WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN - Hiddo J.L. Heerspink; Meg Jardine; Donald E. Kohan; Richard A. Lafayette; Adeera Levin; Adrian Liew; Hong Zhang; Todd Gray; Khushboo Sheth; Marianne Camargo; Ronny Renfurm; Andrew King; et al. (Kidney International Reports)